Kodiak Sciences (KOD) Competitors $10.20 +0.49 (+5.05%) Closing price 04:00 PM EasternExtended Trading$9.89 -0.31 (-3.04%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KOD vs. OCUL, AGIO, DNLI, GLPG, IDYA, SRPT, BLTE, HRMY, IRON, and MESOShould you be buying Kodiak Sciences stock or one of its competitors? The main competitors of Kodiak Sciences include Ocular Therapeutix (OCUL), Agios Pharmaceuticals (AGIO), Denali Therapeutics (DNLI), Galapagos (GLPG), IDEAYA Biosciences (IDYA), Sarepta Therapeutics (SRPT), Belite Bio (BLTE), Harmony Biosciences (HRMY), Disc Medicine (IRON), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry. Kodiak Sciences vs. Its Competitors Ocular Therapeutix Agios Pharmaceuticals Denali Therapeutics Galapagos IDEAYA Biosciences Sarepta Therapeutics Belite Bio Harmony Biosciences Disc Medicine Mesoblast Ocular Therapeutix (NASDAQ:OCUL) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation. Do institutionals and insiders believe in OCUL or KOD? 59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 2.3% of Ocular Therapeutix shares are owned by company insiders. Comparatively, 45.9% of Kodiak Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, OCUL or KOD? Ocular Therapeutix has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Kodiak Sciences has a beta of 2.41, indicating that its share price is 141% more volatile than the S&P 500. Do analysts rate OCUL or KOD? Ocular Therapeutix presently has a consensus price target of $17.20, indicating a potential upside of 39.84%. Kodiak Sciences has a consensus price target of $11.75, indicating a potential upside of 15.20%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, analysts plainly believe Ocular Therapeutix is more favorable than Kodiak Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Kodiak Sciences 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is OCUL or KOD more profitable? Kodiak Sciences has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -382.51%. Ocular Therapeutix's return on equity of -71.92% beat Kodiak Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-382.51% -71.92% -49.36% Kodiak Sciences N/A -155.27%-63.29% Does the media refer more to OCUL or KOD? In the previous week, Kodiak Sciences had 22 more articles in the media than Ocular Therapeutix. MarketBeat recorded 22 mentions for Kodiak Sciences and 0 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 1.10 beat Kodiak Sciences' score of 0.40 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Overall Sentiment Ocular Therapeutix Positive Kodiak Sciences Neutral Which has preferable valuation and earnings, OCUL or KOD? Kodiak Sciences has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$63.72M33.59-$193.51M-$1.28-9.61Kodiak SciencesN/AN/A-$176.21M-$3.80-2.68 SummaryOcular Therapeutix beats Kodiak Sciences on 8 of the 14 factors compared between the two stocks. Get Kodiak Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KOD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KOD vs. The Competition Export to ExcelMetricKodiak SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$512.90M$3.09B$5.82B$9.73BDividend YieldN/A2.23%3.84%4.09%P/E RatioN/A21.1431.1525.97Price / SalesN/A401.49476.16171.70Price / CashN/A43.0937.1558.38Price / Book7.678.079.116.39Net Income-$176.21M-$54.72M$3.26B$265.66M7 Day Performance-3.50%2.62%2.11%1.98%1 Month Performance82.80%7.63%5.12%1.33%1 Year Performance280.60%13.11%31.25%21.15% Kodiak Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KODKodiak Sciences3.2267 of 5 stars$10.20+5.0%$11.75+15.2%+248.0%$512.90MN/A-2.6890Analyst RevisionOCULOcular Therapeutix4.1181 of 5 stars$12.31-2.5%$17.20+39.7%+31.4%$2.20B$63.72M-9.62230AGIOAgios Pharmaceuticals4.3577 of 5 stars$37.45+1.2%$56.33+50.4%-18.9%$2.15B$36.50M3.40390Positive NewsDNLIDenali Therapeutics4.2122 of 5 stars$14.82+0.8%$33.62+126.8%-39.1%$2.15B$330.53M-5.29430News CoverageGLPGGalapagos0.133 of 5 stars$32.91+1.4%$25.33-23.0%+26.6%$2.14B$275.61M0.001,310Positive NewsIDYAIDEAYA Biosciences4.5409 of 5 stars$24.75+1.7%$48.09+94.3%-38.0%$2.13B$7M-6.5380SRPTSarepta Therapeutics4.641 of 5 stars$20.99-3.8%$43.63+107.8%-86.0%$2.13B$1.90B-24.131,372Trending NewsAnalyst ForecastShort Interest ↑BLTEBelite Bio2.6287 of 5 stars$64.95-2.5%$96.67+48.8%+32.5%$2.12BN/A-41.9010HRMYHarmony Biosciences4.6084 of 5 stars$36.41-1.2%$51.00+40.1%+1.3%$2.12B$714.73M11.75200Positive NewsIRONDisc Medicine3.5433 of 5 stars$58.84-1.7%$96.18+63.5%+21.2%$2.08BN/A-13.1630MESOMesoblast2.3228 of 5 stars$15.93-2.0%$18.00+13.0%+133.0%$2.08B$5.90M0.0080News CoverageUpcoming Earnings Related Companies and Tools Related Companies OCUL Competitors AGIO Competitors DNLI Competitors GLPG Competitors IDYA Competitors SRPT Competitors BLTE Competitors HRMY Competitors IRON Competitors MESO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KOD) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kodiak Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kodiak Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access